Cargando…
Essential Guide to Blood Coagulation.
Thrombotic and bleeding disorders affect at least 10 million people in the US alone. There has also been a great deal of concern over travel-related deep vein thrombosis and therefore much more interest and research into the field of blood clotting. This new and concise practical guide will cover al...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Wiley,
2013.
|
| Edición: | 2nd ed. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn829459892 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 130309s2013 nyu ob 001 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d UKDOC |d OCLCQ |d DEBSZ |d COO |d OCLCO |d OCLCF |d OCLCQ |d OCLCO |d Z5A |d MERUC |d OCLCQ |d ZCU |d U3W |d CASUM |d OCLCO |d COCUF |d ICG |d INT |d AU@ |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d UKAHL |d OCLCQ |d OCLCA |d UKMGB |d OCLCO |d SFB |d OCLCQ |d OCL |d OCLCO | ||
| 066 | |c (S | ||
| 015 | |a GBC077873 |2 bnb | ||
| 016 | 7 | |a 019817718 |2 Uk | |
| 020 | |a 9781118327678 | ||
| 020 | |a 1118327675 | ||
| 020 | |z 9781118288795 |q (pbk. ; |q alk. paper) | ||
| 020 | |a 9781118327661 |q EPUB | ||
| 020 | |a 1118327667 | ||
| 029 | 1 | |a AU@ |b 000055876645 | |
| 029 | 1 | |a DEBBG |b BV044173244 | |
| 029 | 1 | |a DEBSZ |b 452513103 | |
| 029 | 1 | |a UKMGB |b 019817718 | |
| 035 | |a (OCoLC)829459892 | ||
| 037 | |a 9781118327661 |b Wiley | ||
| 050 | 4 | |a RC647 .C55 E87 2013 | |
| 060 | 4 | |a WH 310 | |
| 082 | 0 | 4 | |a 616.1 |a 616.157 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Antovic, Jovan. | |
| 245 | 1 | 0 | |a Essential Guide to Blood Coagulation. |
| 250 | |a 2nd ed. | ||
| 260 | |a New York : |b Wiley, |c 2013. | ||
| 300 | |a 1 online resource (218 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |6 880-01 |a Schematic presentation of the hemostatic system / Nils Egberg -- Proposals for sampling instructions / Margareta Blombäck and Nils Egberg -- Laboratory investigations / Jovan P. Antovic, Liselotte Onelöv, and Nils Egberg -- Hereditary bleeding disorders / Margareta Holmström and Lars-Göran Lundberg -- Critical bleeding / Maria Bruzelius, Anna Ågren, and Hans Johnsson -- Investigation of increased bleeding tendency / Margareta Holmström and Lars Göran Lundberg -- Venous thrombosis and pulmonary embolism / Anders Carlsson -- Investigations of thromboembolic tendency / Margareta Holmström -- Heart disease / Håkan Wallen and Rickard Linder -- Antiplatelet drug therapy and reversal of its effects / Håkan Wallen, Hans Johnsson, and Bo-Michael Bellander -- New oral anticoagulants : focus on currently approved oral factor Xa and thombin inhibitors / Rickard E. Malmström and Hans Johnsson -- Stroke and transient ischemic attack / Nils Wahlgren and Mia von Euler -- Peripheral artery surgery / Jesper Swedenborg -- Hemostasis in obstetrics and gynecology / Katarina Bremme -- Hemostasis in children / Susanna Ranta and Pia Petrini -- Emergency conditions associated with coagulation : DIC, HIT, and TTP/HUS / Jovan P. Antovic and Margareta Holmström. | |
| 520 | |a Thrombotic and bleeding disorders affect at least 10 million people in the US alone. There has also been a great deal of concern over travel-related deep vein thrombosis and therefore much more interest and research into the field of blood clotting. This new and concise practical guide will cover all the essentials one needs to know when managing thrombotic and bleeding disorders. The field of haematology is undergoing major advances in thrombosis research, including significant additions to recommended treatment protocols. The Essential Guide to Coagulation will distil the most clinically. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Blood |x Coagulation. | |
| 650 | 0 | |a Blood coagulation disorders. | |
| 650 | 1 | 2 | |a Blood Coagulation |
| 650 | 2 | 2 | |a Blood Coagulation Disorders |
| 650 | 2 | 2 | |a Embolism |x physiopathology |
| 650 | 2 | 2 | |a Thrombosis |x physiopathology |
| 650 | 6 | |a Sang |x Coagulation. | |
| 650 | 6 | |a Sang |x Troubles de la coagulation. | |
| 650 | 7 | |a Blood coagulation disorders |2 fast | |
| 650 | 7 | |a Blood |x Coagulation |2 fast | |
| 650 | 7 | |a Coagulació sanguínia. |2 thub | |
| 655 | 7 | |a Llibres electrònics. |2 thub | |
| 700 | 1 | |a Blomb?ck, Margareta. | |
| 776 | 0 | 8 | |i Print version: |a Antovic, Jovan. |t Essential Guide to Blood Coagulation. |d New York : Wiley, ©2013 |z 9781118288795 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=1132829 |z Texto completo |
| 880 | 0 | 0 | |6 505-01/(S |t Part 1 General Hemostasis -- -- |g 1. |t Schematic presentation of the hemostatic system -- -- |g 2. |t Proposals for sampling instructions -- |t Points to note prior to sampling -- |t Sampling time and patient preparation -- |t Referrals for coagulation analyses -- |t Sampling -- |t Analyses of plasma -- |t Technique -- |t For DNA investigation (genetic analyses) -- |t Reference -- -- |g 3. |t Laboratory investigations -- |t Nomenclature -- |t Reference intervals for laboratory investigations -- |t Screening analyses -- |t Pt-Bleeding time -- |t Other proposed analyses when bleeding time is increased in spite of normal platelet count -- |t Special analyses -- |t Coagulation factors -- |t Anticoagulants -- |t Protein C anticoagulant system -- |t Platelet function -- |t Fibrinolysis -- |t Markers of coagulation activation (hypercoagulation markers) -- |t Activating peptides: general remarks -- |t P-prothrombin fragment 1+2 (F1+2) -- |t P-thrombin-antithrombin (TAT) complex -- |t DNA analyses -- |t DNA-based diagnosis of hemophilia A and B -- |t DNA-based diagnosis in VWD -- |t DNA-based diagnosis in other hereditary bleeding disorders -- |t DNA-based diagnosis in thromboembolic disorders -- |t Global hemostatic assays and bedside methods -- |t Endogenous thrombin potential (ETP) -- |t Overall hemostatic potential (OHP) -- |t Thromboelastography (TEG®)/ROTEM®) -- |t Point-of-care tests (POCT) also used as a routine -- |t Useful components in research studies -- |t Fibrin-gel structure -- |t P-plasmin-plasmin inhibitor complex -- |t P-t-PA-PAI complex -- |t P-thrombin time -- |t P-ecarin clotting time -- |t P-C1-esterase inhibitor -- |t P-elastase -- |t P-heparin co-factor II (HC II) -- |t P-plasminogen activator inhibitor 2 (PAI-2) -- |t P-protein C inhibitor -- |t P-APC-protein C inhibitor (PCI) complex -- |t P-Tafi -- |t P-VWF cleaving protease = ADAMTS-13 -- |t P-tissue factor pathway inhibitor (TFPI) -- |t P-tissue factor (TF) -- |t Platelet-activating predictors -- |t P-thromboglobulin (β-TG), P-platelet factor 4 (PF4) -- |t Platelet P-selectin (CD62P) or P-soluble P-selectin -- |t PLT-fibrinogen, PLT-VWF -- |t Microparticles (MP) -- |t Other non-hemostatic variables of importance P/S-CRP -- |t Combinations of assays suggested for various hemostatic abnormalities -- |t References -- |t Part 2 Bleeding Disorders -- -- |g 4. |t Hereditary bleeding disorders -- |t General remarks about hemophilia A and B -- |t General remarks about von Willebrand disease -- |t Factor concentrates used for treatment of hemophilia A and B and VWD in Sweden in 2012 -- |t General remarks about factor concentrates -- |t Treatment strategy in severe forms of hemophilia and VWD -- |t Home/self-treatment -- |t Treatment in trauma and acute bleedings -- |t Recommendations for desired initial plasma concentrations at different types of bleedings -- |t Prophylaxis against joint bleedings -- |t Surgery in patients with bleeding disorders -- |t Tooth extraction in a hemophilia patient -- |t Caution in patients with bleeding disorders -- |t Pain-killing drugs allowed in hemophilia -- |t Other important issues in more severe forms of hemophilia and VWD -- |t Risk of hepatitis -- |t Treatment principles for different types of bleeding disorders (severe, moderate, and milder forms of hemostatic defects) -- |t Hematuria -- |t Nose bleeding -- |t Gum bleeding -- |t Menorrhagia -- |t Pregnancy and delivery -- |t Treatment with tranexamic acid -- |t Contraindication -- |t Rare bleeding disorders -- |t Severe platelet function defect (e.g. Glanzmann thrombasthenia) -- |t Mild hemostatic defects -- |t Blood sampling in bleeding disorders -- |t Bleeding risk charts. |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH25004167 | ||
| 938 | |a 123Library |b 123L |n 94300 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL1132829 | ||
| 994 | |a 92 |b IZTAP | ||